- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02893722
A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment
A Randomized Double Blind Comparison of Atosiban in Patients With Repeated Implantation Failure Undergoing IVF Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background and Rationale With the rapid development of the technology of reproductive medicine, in vitro fertilization embryo transfer (IVF-ET) and its related derivatives have become the most important means for the treatment of infertility. IVF-ET pregnancy rate increased from the initial 10% to current more than 50%, but the repeated implantation failure (RIF) has occurred occasionally, which has become a difficult that perplex IVF-ET clinical practices. There is no uniform definition of RIF at present. Coughlan et al called that the women below 40 years old who experienced at least 3 fresh or frozen periods and failed to transplant 4 and more than 4 high-quality embryos as RIF in 2014 [1]. At present, most of the patients have started the reason screening and inspection spontaneously if the transplantation fails after of transplanting 2 high-quality embryos. But the embryo implantation is a complex process, the etiology of RIF can be roughly summed as the embryo factors, uterine factors, genetic factors, immunological factors and so on, the symptomatic treatment according to different causes can improve the success rate of re-transplantation system [2]. However, in most cases, the etiology of RIF still cannot be explained [3].
In recent years, the influence of uterine contraction on embryo implantation has attracted more and more attention. Studies have shown that no matter it's natural menstrual cycle or fertility cycle, moderate Uterine Contraction (UC) is conducive to embryo implantation, but excessive or strong UC will have a negative impact on embryo implantation, and even the embryos to be implanted to the fallopian tube, cervical or vaginal, and even be discharged of the uterus [4-6].
The estrogen levels of excessively physiological state during the process of ovulation induction of IVF can induce the production ofoxytocin in the endometrial cells, and indirectly lead to the synthesis and release of prostaglandin PGF2α, resulting in increased uterine contraction frequency [7-9]. In 1998, Fanchin et al. found that the frequency of uterine contraction of about 30% of the embryos transplantation patients was higher than 5 times /min, which was significantly correlated to the success rate of low pregnancy [5]. The follow-up studies confirmed by ultrasound showed that the frequency of endometrial contraction induced by ovulation induction cycle of IVF[10] is 5-6 times of the natural cycle. Therefore, in addition to the soft operation of the transplant process, the reduction of uterine excessive contraction by drugs may be an effective measure to improve the success rate of IVF pregnancy.
Atosiban is the antagonist of mixed receptor of pitressin VIA and oxytocin, it competes the oxytocin receptor located on the uterine muscle cell membranes, foetal membrane and deciduas with oxytocin to inhibit contraction of the uterus; at the same time, it inhibits the generation of oxytocin induced uterine endometrial prostate element PGF2 α to increase the endometrial blood flow perfusion. Pierzynski et al first applied Atosiban to the field of reproduction in 2007 for the first time, which made the uterine contraction frequency of a RIF patient who failed to transplant for seven times before the oocyte donation embryo transplant decreased significantly, and successful became pregnant [11]. This report immediately caused the reproductive scientists to apply Atosiban to the clinical study of in vitro assisted reproduction. For the general population, there are still disputes on whether use Atosiban during the embryo transplant [12-14]. The prospective and randomized study of He Ye et al showed that Atosiban can significantly reduce the oxytocin of patients with endometriosis and serum concentrations of PGF2 α, reduce the frequency of uterine contraction and improve the implantation rate of quality blastocyst after freeze-thaw treatment and clinical pregnancy rate [15]. In the RIF population, the retrospective study and prospective cohort studies have shown that using low doses of Atosiban during IVF-ET can increase the implantation rate of fresh and thawed quality embryos and clinical pregnancy rate [16-18], which may improve pregnancy outcomes in patients with RIF. But these studies were not randomized placebo-controlled studies, and their conclusions are still to be verified.
Atosiban is currently a safe and effective tocolytic drug for uncomplicated preterm patients, the patients had accelerated heartbeat, nausea, vomiting, headache, dizziness, flushing, anxiety, tremor and other side effects occasionally. Randomized and double blind controlled trial showed that the side effects with application of Atosiban and placebo in the maternal and child was similar, the difference was not statistically significant [15]. Preclinical studies haven't found that Atosiban has any toxicity to human sperm motility or embryo development in rabbits [20]. It hasn't found the literatures that report the fetal congenital malformations associated with the application of Atosiban. Therefore, the therapeutic dose of Atosiban should be able to be safely used in embryo transfer.
In summary, this study intends to carry out a prospective, randomized, double blind and controlled study to compare the influence of Atosiban and placebo on uterine contraction frequency, endometrial blood flow perfusion, oxytocin and serum concentration of PGF2α, embryo implantation rate and clinical pregnancy rate on the RIF population after fresh embryo transfer, so as to further clarify the curative effect of Atosiban in the treatment of RIF and provide evidence-based basis for Atosiban for application in RIF population.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Zhi Qin Chen, master
- Phone Number: 2078 86-21-54035206
- Email: ptchen1@hotmail.com
Study Contact Backup
- Name: Chuan Ling Tang, docter
- Phone Number: 86-021-20261157
- Email: ttangirl56@sina.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 3 or more than 3 embryo implantation failure histories previously (or the number of high-quality embryos transplanted is >4);
- Age <40 years;
- Ultrasound or HSG showed normal uterine cavity, endometrium on transplantation day is ≥ 8mm;
- There's at least one good quality embryo on transplantation day.
Exclusion Criteria:
- Patients using donor sperm or donor eggs;
- Patients have obvious uterine cavity abnormalities;
- There was a clear hydrosalpinx;
- Natural cycles or IVM patients;
- Patients who cancel the due to the transfer due to various reasons, such as the failure of fertilization, or ovarian transitional stimulus syndrome (OHSS);
- Abnormal karyotype;
- Blastocyst transplantation patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: atosiban
Give drugs 30 minutes before the start of the embryo transfer. First step: give a 37.5 mg Atosiban (Ferring, Germany) to take 0.9 ml, that is, 6.75 mg, conduct intravenous injection in one minute. Second step: for the remaining 4.1 ml, namely 30.75 mg, dilute to 41 ml, use the venous pump to adjust to 24 ml/h, infuse for 1 hour, namely 18 mg. Third step: for the remaining 17 ml, use the venous pump to adjust to 8 ml/h, infuse 2.1 hours, namely 12.75 mg. Total administration time is 3 hours, total dose is 37.5 mg. |
give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
Other Names:
|
Placebo Comparator: 0.9% salain
intravenous injection of 0.9% saline in one minute before transfer.
Then use the same dose of normal saline for intravenous infusion to set the same infusion rate with experimental group, complete the infusion in 3 hours.
|
give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical pregnancy rate
Time Frame: 4 weeks after embryo transfer
|
cases of clinical pregnancies / number of transplantation cycles(per patient)
|
4 weeks after embryo transfer
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
implantation rate
Time Frame: 4 weeks after embryo transfer
|
number of pregnancy fetal bursa / total number of transplantation embryos
|
4 weeks after embryo transfer
|
abortion rate
Time Frame: 6 weeks after embryo transfer
|
abortion cases / number of clinical pregnancy cycles
|
6 weeks after embryo transfer
|
ectopic pregnancy rate
Time Frame: 6 weeks after embryo transfer
|
ectopic pregnancy cases / number of clinical pregnancy cycle
|
6 weeks after embryo transfer
|
frequency of uterine contraction (4 minutes)
Time Frame: 1 hour before and 1 hour after intervention
|
times of uterine contraction/4 minutes
|
1 hour before and 1 hour after intervention
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
uterine artery blood flow index
Time Frame: 1 hour before and 1 hour after intervention
|
1 hour before and 1 hour after intervention
|
oxytocin and PGF2 α serum concentration.
Time Frame: 1 hour before and 1 hour after intervention
|
1 hour before and 1 hour after intervention
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Coughlan C, Ledger W, Wang Q, Liu F, Demirol A, Gurgan T, Cutting R, Ong K, Sallam H, Li TC. Recurrent implantation failure: definition and management. Reprod Biomed Online. 2014 Jan;28(1):14-38. doi: 10.1016/j.rbmo.2013.08.011. Epub 2013 Sep 14.
- Simon A, Laufer N. Repeated implantation failure: clinical approach. Fertil Steril. 2012 May;97(5):1039-43. doi: 10.1016/j.fertnstert.2012.03.010. Epub 2012 Mar 30.
- Margalioth EJ, Ben-Chetrit A, Gal M, Eldar-Geva T. Investigation and treatment of repeated implantation failure following IVF-ET. Hum Reprod. 2006 Dec;21(12):3036-43. doi: 10.1093/humrep/del305. Epub 2006 Aug 12.
- Knutzen V, Stratton CJ, Sher G, McNamee PI, Huang TT, Soto-Albors C. Mock embryo transfer in early luteal phase, the cycle before in vitro fertilization and embryo transfer: a descriptive study. Fertil Steril. 1992 Jan;57(1):156-62.
- Fanchin R, Righini C, Olivennes F, Taylor S, de Ziegler D, Frydman R. Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Hum Reprod. 1998 Jul;13(7):1968-74. doi: 10.1093/humrep/13.7.1968.
- Lesny P, Killick SR, Robinson J, Raven G, Maguiness SD. Junctional zone contractions and embryo transfer: is it safe to use a tenaculum? Hum Reprod. 1999 Sep;14(9):2367-70. doi: 10.1093/humrep/14.9.2367.
- Richter ON, Kubler K, Schmolling J, Kupka M, Reinsberg J, Ulrich U, van der Ven H, Wardelmann E, van der Ven K. Oxytocin receptor gene expression of estrogen-stimulated human myometrium in extracorporeally perfused non-pregnant uteri. Mol Hum Reprod. 2004 May;10(5):339-46. doi: 10.1093/molehr/gah039. Epub 2004 Mar 25.
- Liedman R, Hansson SR, Howe D, Igidbashian S, McLeod A, Russell RJ, Akerlund M. Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea compared with healthy subjects. Gynecol Endocrinol. 2008 Sep;24(9):508-13. doi: 10.1080/09513590802306218.
- Zhu L, Li Y, Xu A. Influence of controlled ovarian hyperstimulation on uterine peristalsis in infertile women. Hum Reprod. 2012 Sep;27(9):2684-9. doi: 10.1093/humrep/des257. Epub 2012 Jul 14.
- Ayoubi JM, Epiney M, Brioschi PA, Fanchin R, Chardonnens D, de Ziegler D. Comparison of changes in uterine contraction frequency after ovulation in the menstrual cycle and in in vitro fertilization cycles. Fertil Steril. 2003 May;79(5):1101-5. doi: 10.1016/s0015-0282(03)00179-1.
- Pierzynski P, Reinheimer TM, Kuczynski W. Oxytocin antagonists may improve infertility treatment. Fertil Steril. 2007 Jul;88(1):213.e19-22. doi: 10.1016/j.fertnstert.2006.09.017. Epub 2007 May 3.
- Moraloglu O, Tonguc E, Var T, Zeyrek T, Batioglu S. Treatment with oxytocin antagonists before embryo transfer may increase implantation rates after IVF. Reprod Biomed Online. 2010 Sep;21(3):338-43. doi: 10.1016/j.rbmo.2010.04.009. Epub 2010 Apr 18.
- Song XR, Zhao XH, Bai XH, Lu YH, Zhang HJ, Wang YX, Lu R. [Application of oxytocin antagonists in thaw embryo transfer]. Zhonghua Fu Chan Ke Za Zhi. 2013 Sep;48(9):667-70. Chinese.
- Ng EH, Li RH, Chen L, Lan VT, Tuong HM, Quan S. A randomized double blind comparison of atosiban in patients undergoing IVF treatment. Hum Reprod. 2014 Dec;29(12):2687-94. doi: 10.1093/humrep/deu263. Epub 2014 Oct 21.
- He Y, Wu H, He X, Xing Q, Zhou P, Cao Y, Wei Z. Administration of atosiban in patients with endometriosis undergoing frozen-thawed embryo transfer: a prospective, randomized study. Fertil Steril. 2016 Aug;106(2):416-22. doi: 10.1016/j.fertnstert.2016.04.019. Epub 2016 Apr 30.
- Lan VT, Khang VN, Nhu GH, Tuong HM. Atosiban improves implantation and pregnancy rates in patients with repeated implantation failure. Reprod Biomed Online. 2012 Sep;25(3):254-60. doi: 10.1016/j.rbmo.2012.05.014. Epub 2012 Jun 16.
- Chou PY, Wu MH, Pan HA, Hung KH, Chang FM. Use of an oxytocin antagonist in in vitro fertilization-embryo transfer for women with repeated implantation failure: a retrospective study. Taiwan J Obstet Gynecol. 2011 Jun;50(2):136-40. doi: 10.1016/j.tjog.2011.04.003.
- Zhang Yue, Zhu Yujing, Luo Haining, et al. Clinical observation on the effect of the patients using Atosiban for frozen thawed embryo transfer after repeated failure of implantation. Chinese Journal of Family Planning,2016,22 (05): 325-328.
- Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille JC, Tabor B, Perry KG, Varner M, Goodwin TM, Lane R, Smith J, Shangold G, Creasy GW. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol. 2000 May;182(5):1173-83. doi: 10.1067/mob.2000.95834.
- Pierzynski P, Gajda B, Smorag Z, Rasmussen AD, Kuczynski W. Effect of atosiban on rabbit embryo development and human sperm motility. Fertil Steril. 2007 May;87(5):1147-52. doi: 10.1016/j.fertnstert.2006.08.089. Epub 2007 Jan 16.
- Tang CL, Li QY, Chen FL, Cai CT, Dong YY, Wu YY, Yang JZ, Zhao M, Chi FL, Hong L, Ai A, Chen MX, Li KM, Teng XM, Chen ZQ. A randomized double blind comparison of atosiban in patients with recurrent implantation failure undergoing IVF treatment. Reprod Biol Endocrinol. 2022 Aug 19;20(1):124. doi: 10.1186/s12958-022-00999-y.
- Craciunas L, Tsampras N, Kollmann M, Raine-Fenning N, Choudhary M. Oxytocin antagonists for assisted reproduction. Cochrane Database Syst Rev. 2021 Sep 1;9(9):CD012375. doi: 10.1002/14651858.CD012375.pub2.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FERRING-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Repeated Implantation Failure
-
Ain Shams UniversityCompletedRepeated Implantation FailureEgypt
-
Assaf-Harofeh Medical CenterUnknownRepeated Implantation Failure
-
ZhangTaoUnknown
-
An Sinh HospitalVietnam National UniversityCompletedRepeated Implantation FailureVietnam
-
University Hospital, GhentCenter for Microbial Ecology and Technology - Ghent UniversityCompletedRepeated Implantation Failure | Normal FertileBelgium
-
Tanta UniversityMansoura University; Benha UniversityRecruitingRepeated Implantation Failure | ICSI Failure | uNatural Killer CellsEgypt
-
Huazhong University of Science and TechnologyRecruitingRepeated Implantation FailureChina
-
ShangHai Ji Ai Genetics & IVF InstituteRecruitingEndometrial Receptivity | Repeated Implantation FailureChina
-
National and Kapodistrian University of AthensCompletedRepeated Implantation FailuresGreece
-
Clinique OvoTerminatedRepeated Embryo Implantation FailureCanada
Clinical Trials on atosiban
-
An Sinh HospitalVietnam National UniversityCompletedRepeated Implantation FailureVietnam
-
GlaxoSmithKlinePPDTerminatedObstetric Labour, PrematureBelgium, Germany, Israel, Italy, Korea, Republic of, Mexico, Spain, Sweden, United Kingdom
-
AZ Jan Palfijn GentOnze Lieve Vrouw HospitalCompleted
-
Radboud University Medical CenterRecruitingEndometriosisNetherlands
-
Bezmialem Vakif UniversityYeditepe UniversityUnknownInfertility, FemaleTurkey
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingPreterm BirthNetherlands
-
ObsEva SAIqvia Pty Ltd; Cytel Inc.; Scope International AG; PhinC DevelopmentActive, not recruitingPreterm LaborSpain, Russian Federation, Vietnam, Czechia, Finland, Israel
-
Polish Mother Memorial Hospital Research InstituteCompleted
-
The University of Hong KongNanfang Hospital of Southern Medical University; Vietnam National UniversityCompleted
-
Tawam HospitalCompleted